Alzamend Neuro, Inc. (ALZN)

$1.04

+0.02 (+1.96%)
Rating:
Recommendation:
-
Symbol ALZN
Price $1.04
Beta 0.000
Volume Avg. 0.34M
Market Cap 99.301M
Shares () -
52 Week Range 0.801-4.14
1y Target Est -
DCF Unlevered ALZN DCF ->
DCF Levered ALZN LDCF ->
ROE -92.11% Strong Sell
ROA -85.16% Strong Sell
Operating Margin -
Debt / Equity 8.73% Neutral
P/E -
P/B 6.94 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ALZN news


Mr. Milton Charles Ault III
Healthcare
Biotechnology
NASDAQ Capital Market

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.